4H-1,3-Benzothiazin-4-one a Promising Class Against MDR/XDR-TB
- PMID: 30834835
- DOI: 10.2174/1568026619666190305130809
4H-1,3-Benzothiazin-4-one a Promising Class Against MDR/XDR-TB
Abstract
Nowadays, tuberculosis (TB) is an important global public health problem, being responsible for millions of TB-related deaths worldwide. Due to the increased number of cases and resistance of Mycobacterium tuberculosis to all drugs used for the treatment of this disease, we desperately need new drugs and strategies that could reduce treatment time with fewer side effects, reduced cost and highly active drugs against resistant strains and latent disease. Considering that, 4H-1,3-benzothiazin-4-one is a promising class of antimycobacterial agents in special against TB-resistant strains being the aim of this review the discussion of different aspects of this chemical class such as synthesis, mechanism of action, medicinal chemistry and combination with other drugs.
Keywords: 4H-1,3-benzothiazin-4-one; Drugs; Multi drug resistant; Mycobacterium tuberculosis; Synthesis; Tuberculosis..
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.
Similar articles
-
Effective therapy with the neuroleptic thioridazine as an adjunct to second line of defence drugs, and the potential that thioridazine offers for new patents that cover a variety of "new uses".Recent Pat Antiinfect Drug Discov. 2011 May;6(2):84-7. doi: 10.2174/157489111796064542. Recent Pat Antiinfect Drug Discov. 2011. PMID: 21548876 Review.
-
XDR-TB, what is it; how is it treated; and why is therapeutic failure so high?Recent Pat Antiinfect Drug Discov. 2011 May;6(2):77-83. doi: 10.2174/157489111796064641. Recent Pat Antiinfect Drug Discov. 2011. PMID: 21595627 Review.
-
Trends in the discovery of new drugs for Mycobacterium tuberculosis therapy with a glance at resistance.Tuberculosis (Edinb). 2018 Mar;109:17-27. doi: 10.1016/j.tube.2017.12.002. Epub 2017 Dec 9. Tuberculosis (Edinb). 2018. PMID: 29559117 Review.
-
DFT based QSAR/QSPR models in the development of novel anti-tuberculosis drugs targeting Mycobacterium tuberculosis.Curr Pharm Des. 2014;20(27):4455-73. doi: 10.2174/1381612819666131118165824. Curr Pharm Des. 2014. PMID: 24245759 Review.
-
Old antibiotics for emerging multidrug-resistant/extensively drug-resistant tuberculosis (MDR/XDR-TB).Int J Antimicrob Agents. 2017 May;49(5):554-557. doi: 10.1016/j.ijantimicag.2017.02.008. Epub 2017 Mar 21. Int J Antimicrob Agents. 2017. PMID: 28336312 Review.
Cited by
-
Discovery of Novel Thiophene-arylamide Derivatives as DprE1 Inhibitors with Potent Antimycobacterial Activities.J Med Chem. 2021 May 13;64(9):6241-6261. doi: 10.1021/acs.jmedchem.1c00263. Epub 2021 Apr 14. J Med Chem. 2021. PMID: 33852302 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources